22 May 2026 - Roche Canada is pleased to share that on 6 May 2026, Canada's Drug Agency recommended Gazyva (obinutuzumab) for public reimbursement. 

This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. 

This positive recommendation expands the pathway to patient access, following Health Canada's authorisation in January 2026.

Read Roche press release